NCT05542043

Brief Summary

This retrospective, monocentric study aims to examine risk factors for postpartum hemorrhage in women with histologically verified placenta accreta. Women with histologically verified placenta accreta are divided into two groups: women with normal blood loss (BV \< 500 ml) versus women with increased blood loss (BV ≥ 500 ml). The clinical data of pregnant women with histologically verified placental disorders, who gave birth in the Women's Clinic University Hospital Basel (USB) between 1986 and 2019, are compared with each other.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,348

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2020

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2021

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

September 5, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

September 15, 2022

Completed
Last Updated

December 7, 2022

Status Verified

December 1, 2022

Enrollment Period

1.3 years

First QC Date

September 5, 2022

Last Update Submit

December 5, 2022

Conditions

Keywords

Placenta HistologyPlacenta accretaPlacenta incretaPlacenta percreta

Outcome Measures

Primary Outcomes (4)

  • Number of Placenta praevia

    Descriptive analysis: Number of women with Placenta praevia (in women with PPH (blood loss ≥ 500 ml) compared to women with normal blood loss (\< 500 ml))

    one time assessment at baseline

  • Number of Caesarean sections

    Descriptive analysis: Number of women with Caesarean section (in women with PPH (blood loss ≥ 500 ml) compared to women with normal blood loss (\< 500 ml))

    one time assessment at baseline

  • Number of women with obesity

    Descriptive analysis: Number of pregnant women with obesity (in women with PPH (blood loss ≥ 500 ml) compared to women with normal blood loss (\< 500 ml))

    one time assessment at baseline

  • Increased maternal age

    Descriptive analysis: Number of pregnant women with increased maternal age (in women with PPH (blood loss ≥ 500 ml) compared to women with normal blood loss (\< 500 ml))

    one time assessment at baseline

Study Arms (2)

Women with normal blood loss (BV < 500 mL)

Other: Data collection

Women with increased blood loss (BV ≥ 500 mL)

Other: Data collection

Interventions

The data includes anamnestic and clinical data from women whose placental histology reveals a diagnosis of placental dysfunction. Maternal data on the following characteristics: age, ethnicity, BMI, pregnancy, parity, number of abortions without curettage, multiple births, previous birth mode. Risk factors for placentation disorders (increased maternal age, increased pregnancy and parity, increased BMI, placenta previa, nicotine abuse, multiple births, hypertension, diabetes, infections, bleeding, abortion curettage, hysteroscopy ± cavum curettage, caesarean section, fibroid removal, Asherman' s syndrome, status after IVF, endometritis) and birth mode. Data on peripartal and postpartum surgical measures.

Women with increased blood loss (BV ≥ 500 mL)Women with normal blood loss (BV < 500 mL)

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Pregnant women with histologically verified placental disorder who gave birth in the USB women's clinic between 1986 and 2019.

You may qualify if:

  • Pregnant women with a histologically verified placental disorder who gave birth at the Women's Hospital USB between 1986 and 2019

You may not qualify if:

  • Existence of a documented refusal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Basel, Women's Clinic, Obstetrics and pregnancy medicine

Basel, 4031, Switzerland

Location

Related Publications (1)

  • Ghaem Maghami N, Helfenstein F, Manegold-Brauer G, Amstad G. Risk factors for postpartum haemorrhage in women with histologically verified placenta accreta spectrum disorders: a retrospective single-centre cross-sectional study. BMC Pregnancy Childbirth. 2023 Nov 11;23(1):786. doi: 10.1186/s12884-023-06103-5.

MeSH Terms

Conditions

Postpartum HemorrhagePlacenta Accreta

Interventions

Data Collection

Condition Hierarchy (Ancestors)

Obstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesPuerperal DisordersUterine HemorrhageHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsPlacenta Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Irene Hoesli, Prof. Dr. med.

    University Hospital Basel, Women's Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 5, 2022

First Posted

September 15, 2022

Study Start

July 1, 2020

Primary Completion

October 31, 2021

Study Completion

October 31, 2021

Last Updated

December 7, 2022

Record last verified: 2022-12

Locations